JP2007506692A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007506692A5 JP2007506692A5 JP2006527332A JP2006527332A JP2007506692A5 JP 2007506692 A5 JP2007506692 A5 JP 2007506692A5 JP 2006527332 A JP2006527332 A JP 2006527332A JP 2006527332 A JP2006527332 A JP 2006527332A JP 2007506692 A5 JP2007506692 A5 JP 2007506692A5
- Authority
- JP
- Japan
- Prior art keywords
- aryl
- alkyl
- diastereomers
- diastereomeric racemates
- general formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 30
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 24
- 239000000203 mixture Substances 0.000 claims 24
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- 239000001257 hydrogen Substances 0.000 claims 17
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 12
- 230000000877 morphologic effect Effects 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 239000002904 solvent Chemical class 0.000 claims 12
- 229920006395 saturated elastomer Polymers 0.000 claims 7
- 125000006413 ring segment Chemical group 0.000 claims 6
- 206010012289 Dementia Diseases 0.000 claims 4
- 206010019280 Heart failures Diseases 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 claims 3
- 150000001721 carbon Chemical group 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 230000002792 vascular Effects 0.000 claims 3
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 206010006458 Bronchitis chronic Diseases 0.000 claims 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 2
- 208000002177 Cataract Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- 206010011878 Deafness Diseases 0.000 claims 2
- 208000002249 Diabetes Complications Diseases 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 206010037423 Pulmonary oedema Diseases 0.000 claims 2
- 208000003782 Raynaud disease Diseases 0.000 claims 2
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 2
- 206010038419 Renal colic Diseases 0.000 claims 2
- 206010063897 Renal ischaemia Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 2
- 229940116211 Vasopressin antagonist Drugs 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 238000002399 angioplasty Methods 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 206010003119 arrhythmia Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000005008 bacterial sepsis Diseases 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000002837 carbocyclic group Chemical group 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 238000007675 cardiac surgery Methods 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 208000007451 chronic bronchitis Diseases 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 231100000867 compulsive behavior Toxicity 0.000 claims 2
- 208000018631 connective tissue disease Diseases 0.000 claims 2
- 229930182912 cyclosporin Natural products 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 230000010370 hearing loss Effects 0.000 claims 2
- 231100000888 hearing loss Toxicity 0.000 claims 2
- 208000016354 hearing loss disease Diseases 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 208000001286 intracranial vasospasm Diseases 0.000 claims 2
- 201000006370 kidney failure Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000005333 pulmonary edema Diseases 0.000 claims 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 230000035939 shock Effects 0.000 claims 2
- 208000007056 sickle cell anemia Diseases 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 230000006016 thyroid dysfunction Effects 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 238000007631 vascular surgery Methods 0.000 claims 2
- 239000003038 vasopressin antagonist Substances 0.000 claims 2
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 206010012655 Diabetic complications Diseases 0.000 claims 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 1
- 208000035202 High altitude pulmonary edema Diseases 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 206010051482 Prostatomegaly Diseases 0.000 claims 1
- 102000050488 Urotensin II Human genes 0.000 claims 1
- 108010018369 Urotensin II Proteins 0.000 claims 1
- 102000012327 Urotensin II receptors Human genes 0.000 claims 1
- 108050002984 Urotensin II receptors Proteins 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 206010051895 acute chest syndrome Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 239000000674 adrenergic antagonist Substances 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000002876 beta blocker Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 230000002232 neuromuscular Effects 0.000 claims 1
- 208000018360 neuromuscular disease Diseases 0.000 claims 1
- 208000007232 portal hypertension Diseases 0.000 claims 1
- 210000003240 portal vein Anatomy 0.000 claims 1
- 201000004240 prostatic hypertrophy Diseases 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- HFNHAPQMXICKCF-USJMABIRSA-N urotensin-ii Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@@H](C(C)C)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)[C@@H](C)O HFNHAPQMXICKCF-USJMABIRSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EPPCT/EP03/10746 | 2003-09-26 | ||
| EP0310746 | 2003-09-26 | ||
| PCT/EP2004/010559 WO2005030209A1 (en) | 2003-09-26 | 2004-09-21 | Pyridine derivatives and use thereof as urotensin ii antagonists |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2007506692A JP2007506692A (ja) | 2007-03-22 |
| JP2007506692A6 JP2007506692A6 (ja) | 2007-07-12 |
| JP2007506692A5 true JP2007506692A5 (enExample) | 2007-11-01 |
| JP4851328B2 JP4851328B2 (ja) | 2012-01-11 |
Family
ID=34384524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006527332A Expired - Fee Related JP4851328B2 (ja) | 2003-09-26 | 2004-09-21 | 新規なピリジン誘導体 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7750161B2 (enExample) |
| EP (1) | EP1670470B1 (enExample) |
| JP (1) | JP4851328B2 (enExample) |
| KR (1) | KR20070014108A (enExample) |
| CN (1) | CN1856305B (enExample) |
| AR (1) | AR045949A1 (enExample) |
| AT (1) | ATE427748T1 (enExample) |
| AU (1) | AU2004275488A1 (enExample) |
| BR (1) | BRPI0414777A (enExample) |
| CA (1) | CA2540196C (enExample) |
| DE (1) | DE602004020486D1 (enExample) |
| IL (1) | IL174497A0 (enExample) |
| MX (1) | MXPA06003264A (enExample) |
| NO (1) | NO20061395L (enExample) |
| RU (1) | RU2006113948A (enExample) |
| TW (1) | TW200526630A (enExample) |
| WO (1) | WO2005030209A1 (enExample) |
| ZA (1) | ZA200602442B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1608319A4 (en) | 2003-04-03 | 2007-02-28 | Univ California | IMPROVED HEMMER FOR SOLUBLE EPOXY HYDROLASE |
| DE10358539A1 (de) * | 2003-12-15 | 2005-07-07 | Merck Patent Gmbh | Carbonsäureamidderivate |
| JP2007532484A (ja) | 2004-03-16 | 2007-11-15 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 可溶性エポキシド加水分解酵素の阻害剤およびエポキシエイコサノイドを用いて腎症を緩和する方法 |
| AR051213A1 (es) * | 2004-10-12 | 2006-12-27 | Actelion Pharmaceuticals Ltd | 1-(2-(4-bencil-4-hidroxi-piperidin-1-il)-etil)-3-(2-metil-quinolin-4-il)-urea como una sal sulfato cristalina |
| TW200630337A (en) * | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| EP1814875A4 (en) | 2004-10-20 | 2010-02-17 | Univ California | IMPROVED INHIBITORS OF SOLUBLE EPOXY HYDROLASE |
| SE0403084D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Chemical process |
| WO2006135694A2 (en) * | 2005-06-10 | 2006-12-21 | Acadia Pharmaceuticals Inc. | Uii-modulating compounds and their use |
| AR059826A1 (es) | 2006-03-13 | 2008-04-30 | Univ California | Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble |
| US8247442B2 (en) * | 2006-03-29 | 2012-08-21 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use |
| TW200812963A (en) * | 2006-04-13 | 2008-03-16 | Euro Celtique Sa | Benzenesulfonamide compounds and the use thereof |
| TW200815353A (en) * | 2006-04-13 | 2008-04-01 | Euro Celtique Sa | Benzenesulfonamide compounds and their use |
| ES2380391T3 (es) * | 2006-12-22 | 2012-05-11 | Actelion Pharmaceuticals Ltd. | Derivados de 5,6,7,8-tetrahidro-imidazo[1,5-a]pirazina |
| US8399486B2 (en) | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
| US8765736B2 (en) * | 2007-09-28 | 2014-07-01 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| KR20100102646A (ko) | 2007-12-11 | 2010-09-24 | 가부시키가이샤 사이토파스파인더 | 카르복스아미드 화합물 및 케모카인 수용체 길항제로서의 이의 용도 |
| WO2012054093A2 (en) | 2010-01-29 | 2012-04-26 | The Regents Of The University Of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE903957A1 (en) | 1989-11-06 | 1991-05-08 | Sanofi Sa | Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present |
| US6159700A (en) | 1997-01-27 | 2000-12-12 | Smithkline Beecham Corporation | Method of finding agonist and antagonist to human and rat GPR14 |
| AUPP003197A0 (en) | 1997-09-03 | 1997-11-20 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| US6331541B1 (en) * | 1998-12-18 | 2001-12-18 | Soo S. Ko | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| ATE302005T1 (de) * | 1998-12-18 | 2005-09-15 | Bristol Myers Squibb Pharma Co | N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren |
| WO2001009088A1 (en) | 1999-07-28 | 2001-02-08 | Kirin Beer Kabushiki Kaisha | Urea derivatives as inhibitors of ccr-3 receptor |
| ATE279923T1 (de) | 1999-12-21 | 2004-11-15 | Smithkline Beecham Corp | Urotensin-ii rezeptorantagonisten |
| EP1244452B1 (en) | 1999-12-21 | 2003-09-17 | SmithKline Beecham Corporation | Carboxamide derivates of pyrrolidine and piperidine as urotensin-ii receptor antagonists |
| AU2441801A (en) | 1999-12-21 | 2001-07-03 | Smithkline Beecham Corporation | Urotensin-ii receptor antagonists |
| CA2402096A1 (en) | 2000-03-07 | 2001-09-13 | Takeda Chemical Industries, Ltd. | Vasoactive agents |
| EP1363881A2 (en) * | 2000-06-21 | 2003-11-26 | Bristol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| EP1295867A4 (en) | 2000-06-28 | 2005-03-30 | Takeda Pharmaceutical | BIPHENYL COMPOUND |
| AU2001271018A1 (en) | 2000-07-04 | 2002-01-14 | Takeda Chemical Industries Ltd. | Gpr14 antagonist |
| EP1351687A4 (en) | 2000-12-11 | 2004-01-21 | Smithkline Beecham Corp | UROTENSIN II RECEPTOR ANTAGONISTS |
| EP1351688A4 (en) | 2000-12-11 | 2006-01-04 | Smithkline Beecham Corp | UROTENSIN-II RECEPTOR ANTAGONISTS |
| EP1359915A4 (en) | 2001-01-26 | 2004-07-21 | Smithkline Beecham | UROTENSIN-II RECEPTOR ANTAGONISTS |
| EP1379523B1 (en) * | 2001-03-27 | 2005-07-27 | Actelion Pharmaceuticals Ltd. | 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists |
| US20040152692A1 (en) | 2001-03-29 | 2004-08-05 | Dashyant Dhanak | Pyrrolidine sulfonamides |
| JP2004524355A (ja) | 2001-03-29 | 2004-08-12 | スミスクライン・ビーチャム・コーポレイション | ピロリジンスルホンアミド |
| JP2004529134A (ja) | 2001-03-29 | 2004-09-24 | スミスクライン・ビーチャム・コーポレイション | ピロリジンスルホンアミド |
| WO2002079188A1 (en) | 2001-03-29 | 2002-10-10 | Smithkline Beecham Corporation | Pyrrolidine sulfonamides |
| WO2002089740A2 (en) | 2001-05-07 | 2002-11-14 | Smithkline Beecham Corporation | Sulfonamides |
| JP2004529170A (ja) | 2001-05-07 | 2004-09-24 | スミスクライン・ビーチャム・コーポレイション | スルホンアミド |
| EP1387679A4 (en) | 2001-05-07 | 2004-08-11 | Smithkline Beecham Corp | SULPHONAMIDES |
| EP1385830A4 (en) | 2001-05-07 | 2005-08-17 | Smithkline Beecham Corp | SULPHONAMIDES |
| AR033879A1 (es) | 2001-05-07 | 2004-01-07 | Smithkline Beecham Corp | Compuesto sulfonamida, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para la obtencion de dicho compuesto |
| US6849635B2 (en) | 2001-05-07 | 2005-02-01 | Smithkline Beecham Corporation | Sulfonamides |
| ES2254772T3 (es) * | 2001-12-04 | 2006-06-16 | Actelion Pharmaceuticals Ltd. | 4-(piperidil-y pirrolidil-alquil-ureido)-quinoleinas como receptores antagonistas de urotensina ii. |
| CA2496624A1 (en) * | 2002-09-17 | 2004-04-01 | Actelion Pharmaceuticals Ltd | 1-pyridin-4-yl-urea derivatives |
| WO2004043368A2 (en) | 2002-11-06 | 2004-05-27 | Smithkline Beecham Corporation | Sulfonamides |
| AR041885A1 (es) | 2002-11-06 | 2005-06-01 | Smithkline Beecham Corp | Compuesto de sulfonamida, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion |
| AU2003291303A1 (en) | 2002-11-06 | 2004-06-03 | Smithkline Beecham Corporation | Sulfonamides |
| AU2003291262A1 (en) | 2002-11-06 | 2004-06-03 | Smithkline Beecham Corporation | Sulfonamides |
| AU2003291255A1 (en) | 2002-11-06 | 2004-06-03 | Smithkline Beecham Corporation | Sulfonamides |
| CA2515780C (en) | 2003-02-20 | 2012-12-11 | Encysive Pharmaceuticals Inc. | Phenylenediamine urotensin-ii receptor antagonists and ccr-9 antagonists |
| WO2004099179A1 (en) | 2003-05-07 | 2004-11-18 | Actelion Pharmaceuticals Ltd | Piperazine-alkyl-ureido derivatives |
-
2004
- 2004-09-21 CA CA2540196A patent/CA2540196C/en not_active Expired - Fee Related
- 2004-09-21 DE DE602004020486T patent/DE602004020486D1/de not_active Expired - Lifetime
- 2004-09-21 KR KR1020067005848A patent/KR20070014108A/ko not_active Withdrawn
- 2004-09-21 AU AU2004275488A patent/AU2004275488A1/en not_active Abandoned
- 2004-09-21 AT AT04765436T patent/ATE427748T1/de not_active IP Right Cessation
- 2004-09-21 RU RU2006113948/04A patent/RU2006113948A/ru unknown
- 2004-09-21 CN CN2004800277254A patent/CN1856305B/zh not_active Expired - Fee Related
- 2004-09-21 BR BRPI0414777-4A patent/BRPI0414777A/pt not_active Application Discontinuation
- 2004-09-21 MX MXPA06003264A patent/MXPA06003264A/es unknown
- 2004-09-21 JP JP2006527332A patent/JP4851328B2/ja not_active Expired - Fee Related
- 2004-09-21 WO PCT/EP2004/010559 patent/WO2005030209A1/en not_active Ceased
- 2004-09-21 EP EP04765436A patent/EP1670470B1/en not_active Expired - Lifetime
- 2004-09-21 US US10/573,516 patent/US7750161B2/en not_active Expired - Fee Related
- 2004-09-24 AR ARP040103475A patent/AR045949A1/es unknown
- 2004-09-24 TW TW093129149A patent/TW200526630A/zh unknown
-
2006
- 2006-03-22 IL IL174497A patent/IL174497A0/en unknown
- 2006-03-24 ZA ZA200602442A patent/ZA200602442B/en unknown
- 2006-03-27 NO NO20061395A patent/NO20061395L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5778353B2 (ja) | アゼチジン化合物、組成物及び可溶性エポキシド加水分解酵素の阻害剤としてのそれらの使用 | |
| JP2006505533A5 (enExample) | ||
| KR102913125B1 (ko) | Lpa 수용체 길항제 및 이의 용도 | |
| US20030203915A1 (en) | Nitric oxide donors, compositions and methods of use related applications | |
| CN112771025B (zh) | 作为rock抑制剂的氘代化合物 | |
| EP2253625A1 (en) | Pyridazinones, the preparation and the use thereof | |
| JP3176935B2 (ja) | ドーパミンリセプタサプタイプ特異性リガンドとしてのｎ―アミノアルキルジベンゾフランカルボキサミド | |
| KR20200024777A (ko) | Ｒｈｏ-관련 단백질 키나아제 억제제, Ｒｈｏ-관련 단백질 키나아제 억제제를 함유하는 약학 조성물, 제조 방법 및 약학 조성물의 용도 | |
| JP2006508970A5 (enExample) | ||
| JP2007016011A (ja) | 抗酸化活性を有する新規な含窒素ヘテロ環化合物、及び該化合物を含有する抗酸化薬 | |
| CN1880306A (zh) | 取代的茚并[1,2－c]异喹啉衍生物及其使用方法 | |
| RU2005111589A (ru) | Производные 1-пиридин-4-илмочевины | |
| WO2003099765A1 (en) | β-ALANINE DERIVATIVE AND USE THEREOF | |
| CN103102352B (zh) | 酪氨酸激酶抑制剂吲哚满酮衍生物 | |
| RU2374228C2 (ru) | Производные 4-фенилпиперидина в качестве ингибиторов ренина | |
| FR2816940A1 (fr) | Derives de 4-(biphenylcarbonylamino)-piperidine, compositions les contenant et leur utilisation | |
| RU2006113948A (ru) | Производные пиридина и их применение в качестве антагонистов уротензина ii | |
| EP1773835A2 (fr) | Derives de pyrido-pyrido-pyrimidine, leur preparation, leur application dans le traitement du cancer | |
| EP1902054B1 (fr) | Derives de pyrido[2,3-d]pyrimidine, leur preparation, leur application en therapeutique | |
| JPH03163074A (ja) | フラン誘導体 | |
| WO2025118148A1 (en) | Antioxidant drug-conjugate modulators of fpr1, compositions comprising the modulator, and methods of using the same | |
| JP2008519826A5 (enExample) | ||
| JP3116256B2 (ja) | （チオ）ウレア誘導体 | |
| JP2009517436A (ja) | 新規なビニル様酸誘導体 | |
| US9522141B2 (en) | Indazole compounds as aldosterone synthase inhibitors |